Collaboration, Licensing and Other Arrangements - Schedule of Revised Anticipated Cash Flows from Transactions Allocated Performance Obligations (Parenthetical) (Detail) - United Therapeutics Corporation - Collaboration and License Agreement $ in Millions |
1 Months Ended | |||
|---|---|---|---|---|
|
Dec. 31, 2022
USD ($)
| ||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||
| Total anticipated cash flows | $ 722.3 | [1] | ||
| Manufacturing Services | ||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||
| Total anticipated cash flows | 722.3 | |||
| Allocated transaction price | 220.8 | |||
| Manufacturing Services | Transaction Price For The Contractual Obligations | ||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||
| Total anticipated cash flows | 120.0 | |||
| Next-Gen R&D Services | Transaction Price For The Performance Obligations | ||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||
| Total anticipated cash flows | $ 602.3 | |||
| ||||